GCVRZ News and Press, Sanofi Contingent Value Right (Expiring 12/31/2020) From 05/14/24

2024-05-14 11:24:32 ET More on BioNTech, Moderna, etc. BioNTech SE 2024 Q1 - Results - Earnings Call Presentation BioNTech SE (BNTX) Q1 2024 Earnings Call Transcript Regeneron: Dissecting The First Quarter Results And Regulatory Setbacks Moderna announces del...

2024-05-11 07:59:50 ET More on Novavax Novavax Ditches 'Going Concern,' Embraces Sanofi Safety Net (Rating Upgrade) Novavax Q1 2024 Earnings Preview: Success In New Commercial COVID Markets Unlikely Novavax, Inc. (NVAX) TD Cowen's 44th Annual Health Care Conference -...

2024-05-10 14:13:46 ET More on Alphabet, Recursion, etc. Recursion Pharmaceuticals, Inc. (RXRX) Q1 2024 Earnings Call Transcript Bronte Capital - Alphabet: Could Not Find Anything We Liked More Google: The Recent Surge Is Far From Over CrowdStrike, Google exp...

2024-05-10 13:50:51 ET Summary Novavax, Inc.'s Sanofi partnership provides much-needed financial support via upfront and milestone payments, stabilizing its finances. Combination vaccines are set to be an essential market, but competitors like Pfizer and Moderna are further along....

2024-05-10 11:15:35 ET More on Novavax Novavax Q1 2024 Earnings Preview: Success In New Commercial COVID Markets Unlikely Novavax, Inc. (NVAX) TD Cowen's 44th Annual Health Care Conference - (Transcript) Novavax: Another Day Older And Deeper In Novavax surges...

2024-05-10 06:59:03 ET More on Novavax Novavax Q1 2024 Earnings Preview: Success In New Commercial COVID Markets Unlikely Novavax, Inc. (NVAX) TD Cowen's 44th Annual Health Care Conference - (Transcript) Novavax: Another Day Older And Deeper In Biggest stock ...

2024-05-02 07:55:40 ET More on Regeneron Pharmaceuticals Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate Regeneron Pharmaceuticals, Inc. (REGN) Leerink Partners Global Biopharma Conference (Transcript) Regeneron Pharmaceuticals, Inc. (REGN) Barclays ...

2024-05-01 14:27:40 ET Summary Sanofi acquired Inbrx to add lung disorders to its treatment portfolio, with an estimated sales peak of €600 million by 2032. The company settled 4,000 lawsuits related to Zantac, which is not expected to impact its balance sheet significantly...

2024-04-30 11:30:18 ET Summary Sanofi beat Q1 earnings estimates with revenue at $11.36 billion and EPS at 97 cents, driven largely by Dupixent. Key drugs like Nexviazyme and Altuviiio showed strong performance, with the former doubling its revenue. Despite a high profitabilit...

2024-04-25 01:38:35 ET More on Sanofi: Sanofi: My Top Pick In Big Pharma Sanofi reportedly lining up banks for consumer products spinoff Sanofi succeeds in late-stage trial for blood disorder candidate Read the full article on Seeking Alpha For furthe...